Simvastatin	NN
inhibits	VBZ
growth	NN
factor	NN
expression	NN
and	CC
modulates	VBZ
profibrogenic	JJ
markers	NNS
in	IN
lung	NN
fibroblasts	NNS
.	.

Simvastatin	NNP
is	VBZ
best	RB
known	VBN
for	IN
its	PRP$
antilipidemic	JJ
action	NN
and	CC
use	NN
in	IN
cardiovascular	JJ
disease	NN
due	JJ
to	TO
its	PRP$
inhibition	NN
of	IN
3-hydroxy-3-methylglutaryl	JJ
CoenzymeA	NN
(	(
HMG	NN
CoA	NN
)	)
reductase	NN
,	,
a	DT
key	JJ
enzyme	NN
in	IN
the	DT
cholesterol	NN
synthesis	NN
pathway	NN
.	.

Inhibition	NN
of	IN
biological	JJ
precursors	NNS
in	IN
this	DT
pathway	NN
also	RB
enables	VBZ
pleiotrophic	JJ
immunomodulatory	JJ
and	CC
anti-inflammatory	JJ
capabilities	NNS
,	,
including	VBG
modulation	NN
of	IN
growth	NN
factor	NN
expression	NN
.	.

Connective-tissue-growth-factor	NN
(	(
CTGF	NN
)	)
and	CC
persistent	JJ
myofibroblast	NN
formation	NN
are	VBP
major	JJ
determinants	NNS
of	IN
the	DT
aggressive	JJ
fibrotic	JJ
disease	NN
,	,
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
.	.

In	IN
this	DT
study	NN
we	PRP
used	VBD
human	JJ
lung	NN
fibroblasts	NNS
derived	VBN
from	IN
healthy	JJ
and	CC
IPF	NN
lungs	NNS
to	TO
examine	VB
Simvastatin	NNP
effects	NNS
on	IN
CTGF	NN
gene	NN
and	CC
protein	NN
expression	NN
,	,
analyzed	VBN
by	IN
RT-PCR	NN
and	CC
ELISA	NN
,	,
respectively	RB
.	.

Simvastatin	NNP
significantly	RB
inhibited	VBD
(	(
P	NN
<	JJR
0.05	CD
)	)
CTGF	NN
gene	NN
and	CC
protein	NN
expression	NN
,	,
overriding	VBG
the	DT
induction	NN
by	IN
transforming-growth-factor-beta1	NN
,	,
a	DT
known	JJ
potent	JJ
inducer	NN
of	IN
CTGF	NN
.	.

Such	JJ
Simvastatin	NN
suppressor	NN
action	NN
on	IN
growth	NN
factor	NN
interaction	NN
was	VBD
reflected	VBN
functionally	RB
on	IN
recognized	VBN
phenotypes	NNS
of	IN
fibrosis	NN
.	.

alpha-smooth-muscle-actin	NN
expression	NN
was	VBD
downregulated	VBN
and	CC
collagen	NN
gel	NN
contraction	NN
reduced	VBN
by	IN
4.94	CD
-	:
and	CC
7.58-fold	RB
in	IN
IMR90	NN
and	CC
HIPF	NN
lung	NN
fibroblasts	NNS
,	,
respectively	RB
,	,
when	WRB
preconditioned	VBN
with	IN
10	CD
microM	NN
Simvastatin	NN
compared	VBN
with	IN
transforming-growth-factor-beta1	NN
treatment	NN
alone	RB
after	IN
24	CD
h	NN
.	.

Our	PRP$
data	NNS
suggest	VBP
that	IN
Simvastatin	NNP
can	MD
modify	VB
critical	JJ
determinants	NNS
of	IN
the	DT
profibrogenic	JJ
machinery	NN
responsible	JJ
for	IN
the	DT
aggressive	JJ
clinical	JJ
profile	NN
of	IN
IPF	NN
,	,
and	CC
potentially	RB
prevents	VBZ
adverse	JJ
lung	NN
parenchymal	JJ
remodeling	NN
associated	VBN
with	IN
persistent	JJ
myofibroblast	NN
formation	NN
.	.

